Alcohol Dependence Clinical Trial
Official title:
Impact of Group Motivational Interviewing for Dually Diagnosed Veterans
Two approaches for providing evidence-based substance abuse treatment (EBT), group motivational interviewing (GMI) and the In-Home-Messaging-Device (IHMD), are interventions that have the characteristic ability for increasing accessibility to evidence-based treatment among patients with substance use problems and are proposed for investigation. GMI is based on motivational interviewing, an intervention that has shown consistent significant effects in promoting treatment retention and reduced substance use among individuals with substance use disorders, and is delivered in a group format. IHMD is a user-friendly computerized Tele-mental Health communication tool that allows interaction through the telephone line between a Veteran and the health care provider in an individual's home or residential placement. The current proposal aims to determine whether GMI and IHMD lead to a significantly greater increase in treatment engagement and reduction in alcohol use compared to a treatment control condition (TCC) among Veterans with a substance use problem and a co-existing psychiatric disorder.
Dually diagnosed Veterans (N = 178) will be recruited from the Charleston, SC VAMC Outpatient
Substance Abuse Treatment Center (SATC) and block randomized to TAU, GMI, or IHMD. Patients
with alcohol dependence or abuse (including drug abuse) and a nonsubstance-related major Axis
I disorder (e.g., bipolar disorder, depression, psychotic disorder) will be eligible for the
study. Participants, who were referred to the study at time of triage or during the
orientation phase of SATC, will be evaluated at baseline and approximately at a 1 and 3-month
follow-up. Primary outcome measures will be alcohol use and treatment utilization as measured
by number of days of alcohol use, number of binge alcohol drinking days, and quantity of
alcohol consumed (in standard drinks, or SECs), and treatment attendance sessions based on
objective CPRS patient medical records (i.e., number of all substance abuse outpatient, other
mental health [e.g., PTSD, depression], and other substance abuse treatment sessions), and
self-reported 12-step (number of self-help AA/NA) sessions, including days consulting with a
12-step or mutual self-help sponsor. Exploratory outcomes measures include number of illicit
drug use days (e.g., cocaine, crack, marijuana, opiates, and sedatives).
Primary questions:
A. Does GMI lead to a significantly greater reduction in alcohol use and an increase in
treatment engagement outcomes in the 3-month follow-up period compared to participants
assigned to TCC?
Hypothesis: Participants who receive GMI will consume less alcohol and will be engaged in and
attend more continuous treatment than participants in TCC in the 3-month follow-up period.
B. Does IHMD lead to a significantly greater reduction in alcohol use and an increase in
treatment engagement outcomes in the 3-month follow-up period compared to participants
assigned to TCC?
Hypothesis: Participants who receive IHMD will consume less alcohol and will be engaged in
and attend more continuous treatment than participants in TCC in the 3-month follow-up
period.
Exploratory question:
Compared to TCC, will GMI and IHMD lead to significantly fewer days of illicit drug use by
3-month follow-up?
Hypothesis: Compared to TCC, GMI and IHMD will result in a significant reduction in days of
illicit drug use by 3-month follow-up.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |